Claude Science: An AI Workbench for Researchers

Claude Science combines databases, coding tools, compute, and research workflows in one unified workspace . According to Reuters and Forbes, the tool provides :

• Pre-configured access to more than 60 scientific databases
• Prebuilt skills for genomics, proteomics, structural biology, and chemistry
• Inline rendering of protein structures and chemical diagrams
• Job management across laptop, cluster, or cloud computing environments
• The ability for scientists to analyze literature, run analyses, create figures and manuscripts, and trace results back to source code and environment
• A starting price around $26 per user

Anthropic emphasized that Claude Science runs on its existing Claude models — no special scientific version was trained. "It is not a new model," Forbes reported, noting the product runs the same Claude everyone already uses, including Opus 4.8 .

The Neglected Diseases Initiative

Alongside its tool-sales strategy, Anthropic is pursuing a neglected diseases initiative focused on conditions such as tuberculosis and malaria. Per STAT News, the company intends to apply its internal drug discovery work to diseases often underfunded by traditional pharma, positioning this as a public-good complement to its commercial tool business . Jonah Cool, head of life sciences partnerships, said Anthropic's goal is to focus on neglected diseases as it creates its internal drug program .

Key Hires and Acquisitions Backing the Biology Push

• Coefficient Bio acquisition (~$400M) — Anthropic acquired this stealth biotech AI startup (fewer than 10 people, mostly ex-Genentech researchers) in an all-stock deal worth just over $400 million in April 2026 . The startup, founded eight months prior by Samuel Stanton and Nathan C. Frey, was working on AI models for biological research . This was Anthropic's largest acquisition and first serious move into a specific vertical market .
• Eric Kauderer-Abrams — Hired to lead Anthropic's life sciences division; he formerly ran AI drug discovery at Verily (Alphabet's life sciences arm) and is the public face of Anthropic's biology push .
• Jonah Cool — Hired as head of life sciences partnerships, bringing biotech industry experience to the team .

How Anthropic Positions Internal Drug Discovery to Complement Pharma

Anthropic executives repeatedly emphasized that the internal drug discovery program is designed to give the company hands-on experience using its own products to solve real scientific problems — not to become a direct pharma competitor . Kauderer-Abrams stated, "Most of our effort is going into making tools for our customers" . The internal biology work generates reference implementations, benchmarks, and feedback loops that improve Claude Science for pharmaceutical customers like Bristol Myers Squibb, which signed a strategic agreement in May 2026 to deploy Claude across its global operations .

"The Single Most Important Thing" at Anthropic

According to CNBC's report from the June 30 event, Kauderer-Abrams said that "the single most important thing" at Anthropic is having the company use its own AI tools to do real science — essentially "dogfooding" its products to prove their utility and drive improvement .

Anthropic's Revenue, Valuation, and Funding

• Valuation: $965 billion post-money after a $65 billion Series H funding round in May 2026, surpassing OpenAI's valuation for the first time .
• Annualized revenue: Sacra estimates Anthropic hit ~$47 billion in annualized revenue in May 2026, up from $9 billion at the end of 2025 . Anthropic's own announcement confirmed a run-rate revenue crossing $47 billion .
• Funding: The $65 billion Series H was led by Altimeter Capital, Dragoneer, Greenoaks, and Sequoia Capital . $15 billion of the round came from prior hyperscaler commitments including Amazon .
• IPO: Anthropic filed confidentially for an IPO on June 1, 2026, at the $965 billion valuation .

The Track Record of AI-Driven Drug Discovery

Despite roughly $60 billion invested in AI-driven drug discovery since 2019, no AI-discovered drug has yet received FDA approval . This sobering track record underscores the high-risk, long-cycle nature of the field Anthropic is entering — and is precisely why the company frames its internal program as long-term R&D rather than a near-term revenue driver .

Additional Related Developments

• Basecamp Research on Claude Science — On June 30, 2026, Basecamp Research announced its EDEN models for antibiotic design and vaccine target prediction are now integrated with Claude Science, enabling scientists to design potent antibiotics and rapidly prioritize vaccine targets through the platform .
• Gates Foundation partnership — In May 2026, Anthropic formed a $200 million partnership with the Gates Foundation, committing grant funding and Claude usage credits for programs in global health, life sciences, education, and economic mobility over four years . The largest part of the partnership focuses on improving health outcomes in low- and middle-income countries .

Claude Science: An AI Workbench for Researchers

Claude Science combines databases, coding tools, compute, and research workflows in one unified workspace . According to Reuters and Forbes, the tool provides :

• Pre-configured access to more than 60 scientific databases
• Prebuilt skills for genomics, proteomics, structural biology, and chemistry
• Inline rendering of protein structures and chemical diagrams
• Job management across laptop, cluster, or cloud computing environments
• The ability for scientists to analyze literature, run analyses, create figures and manuscripts, and trace results back to source code and environment
• A starting price around $26 per user

Anthropic emphasized that Claude Science runs on its existing Claude models — no special scientific version was trained. "It is not a new model," Forbes reported, noting the product runs the same Claude everyone already uses, including Opus 4.8 .

The Neglected Diseases Initiative

Alongside its tool-sales strategy, Anthropic is pursuing a neglected diseases initiative focused on conditions such as tuberculosis and malaria. Per STAT News, the company intends to apply its internal drug discovery work to diseases often underfunded by traditional pharma, positioning this as a public-good complement to its commercial tool business . Jonah Cool, head of life sciences partnerships, said Anthropic's goal is to focus on neglected diseases as it creates its internal drug program .

Key Hires and Acquisitions Backing the Biology Push

• Coefficient Bio acquisition (~$400M) — Anthropic acquired this stealth biotech AI startup (fewer than 10 people, mostly ex-Genentech researchers) in an all-stock deal worth just over $400 million in April 2026 . The startup, founded eight months prior by Samuel Stanton and Nathan C. Frey, was working on AI models for biological research . This was Anthropic's largest acquisition and first serious move into a specific vertical market .
• Eric Kauderer-Abrams — Hired to lead Anthropic's life sciences division; he formerly ran AI drug discovery at Verily (Alphabet's life sciences arm) and is the public face of Anthropic's biology push .
• Jonah Cool — Hired as head of life sciences partnerships, bringing biotech industry experience to the team .

How Anthropic Positions Internal Drug Discovery to Complement Pharma

Anthropic executives repeatedly emphasized that the internal drug discovery program is designed to give the company hands-on experience using its own products to solve real scientific problems — not to become a direct pharma competitor . Kauderer-Abrams stated, "Most of our effort is going into making tools for our customers" . The internal biology work generates reference implementations, benchmarks, and feedback loops that improve Claude Science for pharmaceutical customers like Bristol Myers Squibb, which signed a strategic agreement in May 2026 to deploy Claude across its global operations .

"The Single Most Important Thing" at Anthropic

According to CNBC's report from the June 30 event, Kauderer-Abrams said that "the single most important thing" at Anthropic is having the company use its own AI tools to do real science — essentially "dogfooding" its products to prove their utility and drive improvement .

Anthropic's Revenue, Valuation, and Funding

• Valuation: $965 billion post-money after a $65 billion Series H funding round in May 2026, surpassing OpenAI's valuation for the first time .
• Annualized revenue: Sacra estimates Anthropic hit ~$47 billion in annualized revenue in May 2026, up from $9 billion at the end of 2025 . Anthropic's own announcement confirmed a run-rate revenue crossing $47 billion .
• Funding: The $65 billion Series H was led by Altimeter Capital, Dragoneer, Greenoaks, and Sequoia Capital . $15 billion of the round came from prior hyperscaler commitments including Amazon .
• IPO: Anthropic filed confidentially for an IPO on June 1, 2026, at the $965 billion valuation .

The Track Record of AI-Driven Drug Discovery

Despite roughly $60 billion invested in AI-driven drug discovery since 2019, no AI-discovered drug has yet received FDA approval . This sobering track record underscores the high-risk, long-cycle nature of the field Anthropic is entering — and is precisely why the company frames its internal program as long-term R&D rather than a near-term revenue driver .

Additional Related Developments

• Basecamp Research on Claude Science — On June 30, 2026, Basecamp Research announced its EDEN models for antibiotic design and vaccine target prediction are now integrated with Claude Science, enabling scientists to design potent antibiotics and rapidly prioritize vaccine targets through the platform .
• Gates Foundation partnership — In May 2026, Anthropic formed a $200 million partnership with the Gates Foundation, committing grant funding and Claude usage credits for programs in global health, life sciences, education, and economic mobility over four years . The largest part of the partnership focuses on improving health outcomes in low- and middle-income countries .